Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 4, 2010, Pages 465-470

  Su, Xiaosan ^a   Zhang, Lei ^a   Jin, Liangkun ^a   Ye, Junsong ^a   Guan, Zheng ^a   Chen, Rui ^a   Guo, Tao ^a  

^a First People's Hospital of Kunming   (China)

Author keywords

cytokine induced killer cells; immunotherapy; renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CD56 ANTIGEN; CYTARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; PACLITAXEL; PARACETAMOL; RETINOIC ACID; THALIDOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE KILLER CELL; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; KILLER CELL; LIVER METASTASIS; LUNG METASTASIS; MALE; NEPHRECTOMY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; TARGET CELL; TREATMENT RESPONSE; TUMOR CELL LINE;

AGED; CARCINOMA, RENAL CELL; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956169022     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0762     Document Type: Article

References (27)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. NEJM 1996;335:865.
2. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303.
4. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year followup. J Urol 1992;148:1247.
5. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JA1994;271:907.
6. Negrier S, Escudier B, Lasset C. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. NEJM 1998;338:1272.
7. Atzpodien J, Hoffmann R, Franzke M, et al. Thirteen-year, long-term efficacy of interferon-alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002;95:1045.
8. Wang W, Epler J, Salazar LG, et al. Recognition of breast cancer cells by CD8? cytotoxic T-cell clones specific for NYBR-1. Cancer Res 2006;66:6826.
9. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol 2009;27:130.
10. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31:63.
11. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127.
12. Haas GP, Hillman GG, Redman BG, et al. Immunotherapy of renal cell carcinoma. CA Cancer J Clin 1993;43:177.
13. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokineactivated killer cell phenomenon. Lysis of natural killerresistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823.
14. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or highdose interleukin-2 alone. NEJM 1987;316:889.
15. Whiteside TL, Miescher S, Hurlimann J, et al. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 1986;37:803.
16. Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989.
17. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 1995;13:1939.
18. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1:577.
19. Ridolfi R, Flamini E, Riccobon A, et al. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol Immunother 1998;46:185.
20. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356:802.
21. Kornacker M, Moldenhauer G, Herbst M, et al. Cytokineinduced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 2006;119:1377.
22. Sun S, Li XM, Li XD, et al. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 2005; 20:173.
23. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139.
24. Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8? T cells. Blood 2004;103:3065.
25. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81:1009.
26. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749.
27. Calzascia T, Pellegrini M, Hall H, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007;117:3833.